ALKEM2023-04-012023-06-30 ALKEM2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member ALKEM2023-06-30 ALKEM2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2023-04-01 2024-03-31 2023-08-10 2023-07-31 INR Millions First quarter 11:45:00 13:45:00 2023-08-10 2023-08-10 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2023-04-01 2023-06-30 Unaudited Consolidated 29677200000.00 658400000.00 30335600000.00 8325800000.00 3554700000.00 105200000.00 5676500000.00 297700000.00 724100000.00 8123100000.00 26807100000.00 3528500000.00 0.00 3528500000.00 657800000.00 -7400000.00 650400000.00 0.00 2878100000.00 0.00 0.00 0.00 0.00 2878100000.00 112200000.00 2990300000.00 2867300000.00 10800000.00 2984200000.00 6100000.00 239100000.00 2 23.98 23.98 0.00 0.00 23.98 23.98 1. The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 10 August 2023. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2023. 2. During the previous year ended 31 March 2023, the Group had considered indicators of impairment of its cash-generating units for factors like decline in operational performance, changes in the outlook of future profitability, and weaker market conditions, among other potential indicators. In respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Company, where indicators of impairment were identified & estimated the recoverable amount of the assets based on the fair value less costs to sell. The outcome of this exercise as on 31 March 2023 had resulted in the Group recognizing an impairment loss of Rs 1,029.8 Million in the consolidated financial results under ‘Exceptional item’. Consequently, deferred tax assets pertaining to the above assets were no longer available for utilisation, and had been derecognised in the consolidated financial statements amounting to Rs. 1,197.2 mn. 3. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Other expenses 8123100000.00 Remeasurements of defined benefit plans -39500000.00 -39500000.00 -13100000.00 Foreign currency translation difference of foreign operations 138600000.00 138600000.00 0.00